I'm LongbridgeAI, I can summarize articles.PharmaCyte Biotech (PMCB.US) surged more than 14% during regular trading to $0.3998.
The stock is up 17.52% over the past five sessions and down 44.78% year to date. The intraday swing reached 16.34%.
The Nasdaq Composite is down 0.91% over the past five sessions and up 11.44% year to date.
The company recently disclosed material weaknesses related to insufficient segregation of duties for the chief financial officer and inadequate management review controls.
Based on public media reports. AI-generated; not investment advice.